Clearside Biomedical Announces Multiple Oral Presentations to be Given at the American Society of Retinal Specialists (ASRS) Annual Meeting
- Presentations include clinical experience of the SCS Microinjector™ and a video presentation on suprachoroidally delivered gene therapy -
ALPHARETTA, Ga., July 18, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector™ targeting the suprachoroidal space will be given at the upcoming American Society of Retinal Specialists (ASRS) Annual Meeting taking place July 26-30, 2019 in Chicago, Illinois.
In addition, Thomas A. Ciulla, M.D., MBA, Chief Medical Officer of Clearside, will speak on a panel entitled, “Advancements in Genetic and Regenerative Therapies”, at the Ophthalmology Innovation Summit event (OIS at ASRS) on Thursday, July 25, 2019 from 1:35-2:15 pm Central Time. The agenda for OIS at ASRS can be found here: .
Christine N. Kay, M.D., Vitreo Retinal Associates; Affiliate Assistant Professor in the Department of Ophthalmology, University of South Florida
Title: Suprachoroidally delivered gene therapy via non-viral DNA nanoparticles
Date: Video presentation available as a Paper-on-Demand
Michael S. Ip, M.D., Doheny Eye Institute, David Geffen School of Medicine at University of California Los Angeles, CA
Symposium: Diabetic Retinopathy Part I
Title: Suprachoroidal CLS-TA Plus Aflibercept Compared With Aflibercept Monotherapy for Diabetic Macular Edema (DME): Results of a Phase 2 Trial
Date: Monday, July 29, 2019
Time: 11:10 am
Christopher R. Henry, M.D., Retina Consultants of Houston
Symposium: Inflammatory and Infectious Diseases
Title: Suprachoroidal CLS-TA Improves Patient Outcomes in Uveitis of All Anatomic Subtypes: Results of the Phase 3 PEACHTREE Study
Date: Tuesday, July 30, 2019
Time: 10:26 am
Pauline T. Merrill, M.D., Illinois Retina Associates; Assistant Professor in the Department of Ophthalmology, Rush University Medical Center
Symposium: Inflammatory and Infectious Diseases
Title: Suprachoroidally Injected CLS-TA in Uveitis Maintains Efficacy Outcomes Through 48 Weeks: Results of the MAGNOLIA Phase 3 Extension Study
Date: Tuesday, July 30, 2019
Time: 10:30 am
Milan Shah, M.D., Midwest Eye Institute
Symposium: Instrumentation and Devices
Title: Clinical Experience With the SCS Microinjector™ for Suprachoroidal Injections by Ophthalmologists
Date: Tuesday, July 30, 2019
Time: 12:12 pm
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to work with established medications, new formulations of medicines, as well as future therapeutic innovations such as gene therapy. Clearside is headquartered in Alpharetta, GA. For more information, please visit .
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential benefits of the SCS injection platform and the potential approval and commercialization of XIPERE for the treatment of macular edema associated with uveitis. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 15, 2019, and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
(678) 430-8206
Source: Clearside Biomedical, Inc.
